GlobeNewswire

Appian Optimizes the Digital Workforce with Appian Robotic Workforce Manager Solution for Blue Prism

Del

Low-code leader streamlines RPA administration and human hand-offs to increase business performance

RESTON, Va., May 14, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) today announced the availability of the new Appian Robotic Workforce Manager solution for Blue Prism. The solution, designed specifically for users of Blue Prism’s connected-robotic process automation (RPA) software, enables superior management of the digital workforce and optimized coordination between robots and humans.

The solution enhances visibility into robotic processes, and gives human workers greater control over when and how to invoke, prioritize, and coordinate work with digital workers. It also improves visibility, compliance and scalability of RPA implementations.

Organizations such as S&P, OCC and many others use Appian and Blue Prism. At Appian World 2019, Aegon, Unione Fiduciaria, and Queensland University of Technology are presenting on the benefits of combining these technologies.

"Using Appian and Blue Prism together gives us greater power in automating complex processes," said Adeel Javed, Manager of Process Automation at OCC, the world's largest equity derivatives clearing organization. "Combining the two products extends the reach of our automation initiatives and enables centralized management of the entire workforce.”

Features of the solution include:

  • Total visibility into the digital workforce on any device (web or mobile): The solution provides pre-built business reports and dashboards to track and manage robots across applications. Automation Center of Excellence leaders can provide this information to the business owners of respective RPA processes through web and mobile interfaces. 
  • Automation of work hand-offs between robots and people: The solution provides a global case management and exception management framework that automates “human-in-the-loop” tasks and eliminates manual hand-offs. This improves traceability, compliance, and overall SLA management across automated processes.
  • Automation Manager: The solution allows business process owners to request new automation and manage the entire life cycle of adding new automations. This gives the Automation COE full visibility, compliance and control over all enterprise-wide RPA deployments. For companies that are building many RPA processes, it becomes critical to track and prioritize new RPA processes and ongoing management of existing RPA processes.
  • Assisted Automation and Business Scheduling: With the new solution, process owners can now invoke RPA processes on-demand, or schedule them to run at a later time, on the web or mobile devices.
  • Business Decision Management: Blue Prism users now have access to Appian’s business-friendly Decision Designer. The solution allows Blue Prism users to model complex logic in a simple way and use it anywhere within an RPA process. Spreadsheets and lines of complex IT-owned code are no longer needed to define business logic.

Linda Dotts, SVP Global Partner Strategy and Programs for Blue Prism, said, "Appian's Robotic Workforce Manager solution for Blue Prism provides incredible levels of visibility and self-service to business users and process owners involved with RPA implementations. The solution is a perfect example of how our connected-RPA vision, when coupled with a technology partner, can help drive broader business impact and transformation for our clients."

In addition to the Robotic Workforce Manager, Appian also released a series of no-code integration plug-ins for designers and administrators in the Blue Prism environment. Called “Appian Skills,” they are drag-and-drop integrations that make it easy for Blue Prism developers to connect with Appian.

New Appian Skills for Blue Prism include:

  • Assign Task to Appian User - Passes relevant information to Appian to automate human-in-the-loop tasks
  • Send Data to Appian - Sends information to create or update an Appian Record
  • Get Data from Appian - Pulls the latest information from Appian Records
  • Use Appian Rule - Uses Appian business rules to automate complex decisions

Prittam Bagani, Director of Product Strategy at Appian, said, “The Robotic Workforce Manager stems from our strategic partnership with Blue Prism and was built in collaboration with our joint customers. The solution activates the next-generation enterprise workforce of people and software robots. It provides enterprise automation leaders with the visibility, governance and product capabilities to scale their automation program. The result is greater business impact.” 

Appian and S&P Global will co-present a session on RPA success at the May 22-23 Blue Prism World conference in Orlando, FL.

For more information on Appian RPA with Blue Prism, visit https://www.appian.com/platform/robotic-process-automation-rpa/.

About Appian
Appian provides a low-code development platform that accelerates the creation of high-impact business applications. Many of the world’s largest organizations use Appian applications to improve customer experience, achieve operational excellence, and simplify global risk management and compliance. For more information, visit www.appian.com.

For Information Contact:
Nicole Greggs
Director of Media Relations
+1 703-260-7868
nicole.greggs@appian.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Biome Grow Inc. to Announce First Quarter Fiscal 2019 Financial Results.24.5.2019 19:08:00 CESTPressemelding

TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO, OTCQB: BIOIF, 6OTA:GR) will release its financial results for the first quarter ended March 31, 2019 before market open on May 29, 2019. Following the release of its first quarter 2019 financial results, Biome will host a conference call and audio webcast with Khurram Malik, CEO at 8:30am Eastern Time May 29, 2019. Webcast information A live audio webcast will be available at https://event.on24.com/wcc/r/2015980/CEAD1B37BDD7710D021A38D2B79B5C45 Calling Information Toll Free Dial-In Number: 1 (866) 211 3199 International Dial-In Number (647) 689 6601 Conference ID 8693906 About Biome Biome wholly owns five subsidiaries, including: The Back Home Medical Cannabis Corporation, a company incorporated under the laws of the Province of Newfoundland and Labrador and in the late stages of applying for a license under the Cannabis Act; Great Lakes Cannabis, a company incorporated under the laws of the

Jason Lamb of Gates Foundation Named New Chair of CGAP’s Executive Committee24.5.2019 17:04:00 CESTPressemelding

CGAP CEO calls for renewed focus on retail credit to support growth and jobs for the poor Beirut, Lebanon, May 24, 2019 (GLOBE NEWSWIRE) -- Jason Lamb from the Bill & Melinda Gates Foundation, was elected chair of the Executive Committee for The Consultative Group to Assist the Poor (CGAP) at its annual meeting on Wednesday. Lamb will succeed Carolina Trivelli, senior researcher at the Instituto de Estudios Peruanos and Peru’s former Minister of Development and Social Inclusion. Under Trivelli’s leadership CGAP adopted its new five-year strategy and theory of change that places empowering the poor through financial services to capture opportunities and build resilience at the heart of CGAP’s work. At the Gates Foundation, Lamb is Deputy Director, Financial Services for the Poor (FSP) and manages focus country implementation in Bangladesh, Pakistan, Indonesia, Nigeria, Tanzania, Kenya and Uganda. He has served on CGAP’s Executive Committee, which functions like a board of directors prov

Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CESTPressemelding

New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus

Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CESTPressemelding

ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r

Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CESTPressemelding

American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and

XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CESTPressemelding

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi